Concordia International Corp. (NASDAQ: CXRX) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Concordia International Corp. to similar businesses based on the strength of its earnings, risk, institutional ownership, analyst recommendations, profitability, dividends and valuation.

Valuation & Earnings

This table compares Concordia International Corp. and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Concordia International Corp. $677.25 million $326.58 million -0.04
Concordia International Corp. Competitors $7.86 billion $2.50 billion 0.98

Concordia International Corp.’s competitors have higher revenue and earnings than Concordia International Corp.. Concordia International Corp. is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Concordia International Corp. and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Concordia International Corp. -269.97% -83.96% -0.62%
Concordia International Corp. Competitors -3,615.35% -50.25% -8.94%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Concordia International Corp. and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concordia International Corp. 5 1 0 0 1.17
Concordia International Corp. Competitors 940 3771 5984 164 2.49

Concordia International Corp. currently has a consensus price target of $8.00, indicating a potential upside of 506.06%. As a group, “Pharmaceuticals” companies have a potential upside of 25.95%. Given Concordia International Corp.’s higher probable upside, analysts clearly believe Concordia International Corp. is more favorable than its competitors.

Insider & Institutional Ownership

9.3% of Concordia International Corp. shares are held by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Concordia International Corp. has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Concordia International Corp.’s competitors have a beta of 0.86, indicating that their average share price is 14% less volatile than the S&P 500.


Concordia International Corp. competitors beat Concordia International Corp. on 9 of the 12 factors compared.

Concordia International Corp. Company Profile

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings for Concordia International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International Corp. and related companies with's FREE daily email newsletter.